NEP-3R
Triple-Receptor Agonist Peptide (GLP-1/GIP/Glucagon)
Molecular Details
Overview
NEP-3R is a synthetic research peptide designed to simultaneously engage three distinct metabolic receptor pathways: the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Multi-receptor agonism represents a newer area of metabolic research, exploring how simultaneous activation of these pathways affects energy homeostasis, glucose regulation, and lipid metabolism.
Published Research
Triple-Agonist Metabolic Effects
Phase 2 clinical trial · 2023A 48-week randomized controlled trial studying a triple-receptor agonist peptide demonstrated significant body weight reduction compared to placebo, along with parallel improvements in fasting glucose levels and other metabolic markers.
Glucose Homeostasis in Type 2 Diabetes Models
Phase 2 clinical trial · 2023Multi-pathway peptide agonism was evaluated in subjects with type 2 diabetes, demonstrating meaningful reductions in glycated hemoglobin through combined mechanisms of improved insulin sensitivity and reduced hepatic glucose production.
Hepatic Fat Reduction
Phase 2a trial · 2024A 48-week randomized study showed dose-dependent liver fat reduction with triple-receptor agonist treatment, demonstrating multiple metabolic improvements beyond weight management alone.
Multi-Pathway Metabolic Signaling
Preclinical / Review · 2024Systematic reviews of triple-agonist compounds have synthesized efficacy and safety data across multiple indications, establishing the mechanistic basis for simultaneous GLP-1, GIP, and glucagon receptor engagement.
Storage & Handling
Store lyophilized powder at –20°C or –80°C for long-term storage. Use sterile buffer systems (pH 5–6) for reconstitution. Protect from light and moisture. Avoid repeated freeze-thaw cycles.
For research purposes only. Not intended for human consumption. This profile summarizes published preclinical literature and does not constitute medical, clinical, or dosage guidance.